CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Ironwood Pharmaceuticals, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Ironwood Pharmaceuticals, Inc.
100 Summer Street, Suite 2300
Phone: (617) 621-7722p:617 621-7722 BOSTON, MA  02110  United States Ticker: IRWDIRWD
Business Summary
Ironwood Pharmaceuticals, Inc. is a gastrointestinal (GI) healthcare company engaged in advancing the treatment of GI diseases and redefining the standard of care for GI patients. It is engaged in the development of LINZESS (linaclotide) for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Linaclotide is also approved for the treatment of functional constipation in pediatric patients ages 6-17 years old. It is advancing apraglutide, a long-acting synthetic glucagon-like peptide-2 (GLP-2) analog being developed for rare gastrointestinal diseases, including short bowel syndrome with intestinal failure (SBS-IF) as well as several earlier stage assets. It is advancing IW-3300, a GC-C agonist, for the potential treatment of visceral pain conditions, such as interstitial cystitis/bladder pain syndrome (IC/BPS), and endometriosis. It is also developing CNP-104 for the treatment of PBC, a rare autoimmune disease targeting the liver.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Julie H.Mchugh 59 4/1/2019 2/12/2014
Chief Executive Officer, Director Thomas A.Mccourt 66 6/4/2021 9/8/2009
Senior Vice President, Chief Operating Officer, Chief Financial Officer Sravan K.Emany 46 6/18/2024 12/6/2021
7 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
VectivBio Holding AG Aeschenvorstadt 36 BASEL Switzerland
Comet Therapeutics, Inc. 610 Main Street Cambridge MA United States

Business Names
Business Name
Comet Therapeutics, Inc.
GlyPharma Therapeutic Inc (Canada)
I76
9 additional Business Names available in full report.

General Information
Number of Employees: 267 (As of 12/31/2023)
Outstanding Shares: 160,028,388 (As of 10/31/2024)
Shareholders: 29
Stock Exchange: NASD
Federal Tax Id: 043404176
Fax Number: (617) 494-0480


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024